Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.

S'inscrire

PAVM

PAVmed (PAVM)

PAVmed Inc

De:

Actualités Réglementées

Mots clefs:

Trier par:

Actualités Non-réglementées

Showing the most relevant articles for your search:NASDAQ:PAVM

1 2 3 4 5 6 7 8 9 10 Suivant >>

Date	Heure	Source	Titre	Symbole	Société
20/11/2024	13h56	PR Newswire (US)	Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test	NASDAQ:PAVM	PAVmed Inc
18/11/2024	14h15	PR Newswire (US)	Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum	NASDAQ:PAVM	PAVmed Inc
14/11/2024	14h01	PR Newswire (US)	PAVmed Provides Business Update and Third Quarter 2024 Financial Results	NASDAQ:PAVM	PAVmed Inc
07/11/2024	14h01	PR Newswire (US)	Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication	NASDAQ:PAVM	PAVmed Inc
05/11/2024	14h01	PR Newswire (US)	Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers	NASDAQ:PAVM	PAVmed Inc
31/10/2024	13h31	PR Newswire (US)	PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024	NASDAQ:PAVM	PAVmed Inc
30/10/2024	13h31	PR Newswire (US)	Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024	NASDAQ:PAVM	PAVmed Inc
15/10/2024	13h51	PR Newswire (US)	Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test	NASDAQ:PAVM	PAVmed Inc
10/10/2024	13h51	PR Newswire (US)	PAVmed Subsidiary, Veris Health, Awarded $1.8 Million NIH Grant to Enhance Cancer Care	NASDAQ:PAVM	PAVmed Inc
09/10/2024	14h01	PR Newswire (US)	Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit	NASDAQ:PAVM	PAVmed Inc
08/10/2024	13h49	PR Newswire (US)	Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024	NASDAQ:PAVM	PAVmed Inc
01/10/2024	14h01	PR Newswire (US)	Lucid Diagnostics Holds Inaugural #CheckYourFoodTube Precancer Testing Event for Former NFL Players	NASDAQ:PAVM	PAVmed Inc
24/09/2024	14h01	PR Newswire (US)	American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer Test	NASDAQ:PAVM	PAVmed Inc
16/09/2024	22h30	PR Newswire (US)	PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements	NASDAQ:PAVM	PAVmed Inc
10/09/2024	13h56	PR Newswire (US)	Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress	NASDAQ:PAVM	PAVmed Inc
03/09/2024	13h51	PR Newswire (US)	Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health	NASDAQ:PAVM	PAVmed Inc
20/08/2024	14h16	PR Newswire (US)	Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard® for Early Detection of Esophageal Precancer and Cancer	NASDAQ:PAVM	PAVmed Inc
13/08/2024	14h18	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PAVM	PAVmed Inc
13/08/2024	14h16	PR Newswire (US)	The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard® to Enhance Early Detection of Esophageal Cancer	NASDAQ:PAVM	PAVmed Inc
13/08/2024	14h01	PR Newswire (US)	PAVmed Provides Business Update and Second Quarter 2024 Financial Results	NASDAQ:PAVM	PAVmed Inc
12/08/2024	22h08	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:PAVM	PAVmed Inc
12/08/2024	14h07	PR Newswire (US)	Lucid Diagnostics Provides Business Update and Second Quarter 2024 Financial Results	NASDAQ:PAVM	PAVmed Inc
08/08/2024	14h31	PR Newswire (US)	Lucid Diagnostics Holds First Major Directly-Contracted EsoGuard® #CheckYourFoodTube Precancer Testing Event	NASDAQ:PAVM	PAVmed Inc
06/08/2024	14h15	PR Newswire (US)	Lucid Diagnostics Announces Positive Data from ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing	NASDAQ:PAVM	PAVmed Inc
05/08/2024	14h15	PR Newswire (US)	Lucid Diagnostics to Participate in Upcoming Investor Conferences	NASDAQ:PAVM	PAVmed Inc
30/07/2024	14h15	PR Newswire (US)	PAVmed to Hold a Business Update Conference Call and Webcast on August 13, 2024	NASDAQ:PAVM	PAVmed Inc
29/07/2024	14h15	PR Newswire (US)	Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 12, 2024	NASDAQ:PAVM	PAVmed Inc
23/07/2024	14h01	PR Newswire (US)	Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume	NASDAQ:PAVM	PAVmed Inc
11/07/2024	14h31	PR Newswire (US)	Lucid Diagnostics Launches New Corporate Website	NASDAQ:PAVM	PAVmed Inc
02/07/2024	13h55	PR Newswire (US)	Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population	NASDAQ:PAVM	PAVmed Inc

Showing the most relevant articles for your search:NASDAQ:PAVM

1 2 3 4 5 6 7 8 9 10 Suivant >>

Delayed Upgrade Clock

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales